Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Au, W. Y.
Right arrow Articles by Kwong, Y. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Au, W. Y.
Right arrow Articles by Kwong, Y. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:752-757, 2003
© 2003 European Society for Medical Oncology

Original Paper

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

W. Y. Au1, A. K. W. Lie1, C. S. Chim1, R. Liang1, S. K. Ma2, C. H. Chan3, Y. K. Mak3, Y. T. Chen3, C. C. So4, Y. M. Yeung5, S. F. Yip5, L. G. Wong5, J. C. Chan6, S. Y. Liu6 and Y. L. Kwong1,+

Departments of 1 Medicine and 2 Pathology, Queen Mary Hospital, Hong Kong; Departments of 3 Medicine and 4 Pathology, Queen Elizabeth Hospital, Hong Kong; 5 Department of Medicine, Tuen Mun Hospital, Hong Kong; 6 Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, People’s Republic of China

Received 26 August 2002; revised 19 November 2002; accepted 3 December 2002

Background:

The best overall treatment strategy for patients with acute promyelocytic leukaemia (APL) in relapse with chemotherapy, bone marrow transplantation (BMT) or arsenic trioxide (As2O3) based therapy remains undefined.

Patients and methods:

We reviewed the clinical course and treatment outcome of 143 APL cases seen in four major hospitals in Hong Kong over a 10-year period.

Results:

Complete remission (CR) was attained in 113 cases (79%) with all-trans retinoic acid (ATRA) and chemotherapy. Relapse occurred at a median of 16 months in 54 cases, with a 3-year disease free survival of 56%. Post-relapse treatment was successful in 41 cases (76%), giving an actuarial 3-year overall survival (OS) of 81% from CR1. Three different protocols were used: chemotherapy alone (n = 19), allogeneic BMT (n = 14) and an As2O3-based regimen (n = 21). Chemotherapy was associated with the highest treatment-related mortality (TRM) at 53%, giving a CR2 rate of 47%. TRM was 36% for BMT. The CR2 rate for the As2O3-based regimen was 100%, with no TRM. However, 38% of As2O3 treated patients had subsequent relapses, which were further salvaged in 75% by combined As2O3 plus ATRA. The actuarial OS for the three protocols leveled off by 2 years at 82% for As2O3, 43% for BMT and 23% for chemotherapy (P = 0.0004).

Conclusions:

Our results suggest that As2O3 may be superior to chemotherapy and BMT for the treatment of APL in relapse.

Key words: acute promyelocytic leukaemia, allogeneic bone marrow transplantation, arsenic trioxide, relapse


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood, February 26, 2009; 113(9): 1875 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C S Chim, W W L Chan, and Y L Kwong
Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias
J. Clin. Pathol., July 1, 2008; 61(7): 844 - 847.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ghavamzadeh, K. Alimoghaddam, S. H. Ghaffari, S. Rostami, M. Jahani, R. Hosseini, A. Mossavi, E. Baybordi, A. Khodabadeh, M. Iravani, et al.
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
Ann. Onc., January 1, 2006; 17(1): 131 - 134.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.